These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 8797588

  • 1. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
    Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ.
    Cancer Res; 1996 Sep 15; 56(18):4171-9. PubMed ID: 8797588
    [Abstract] [Full Text] [Related]

  • 2. RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.
    Slate DL, Bruno NA, Casey SM, Zutshi N, Garvin LJ, Wu H, Pfister JR.
    Anticancer Res; 1995 Sep 15; 15(3):811-4. PubMed ID: 7645963
    [Abstract] [Full Text] [Related]

  • 3. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC, Guan Y, Soenen DR, Danishefsky SJ, Boger DL.
    Cancer Chemother Pharmacol; 2005 Oct 15; 56(4):379-90. PubMed ID: 15875185
    [Abstract] [Full Text] [Related]

  • 4. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.
    Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA.
    J Pharmacol Exp Ther; 1999 Aug 15; 290(2):854-62. PubMed ID: 10411602
    [Abstract] [Full Text] [Related]

  • 5. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD.
    Cancer Res; 2000 Jun 01; 60(11):2964-72. PubMed ID: 10850444
    [Abstract] [Full Text] [Related]

  • 6. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic.
    Dantzig AH, Law KL, Cao J, Starling JJ.
    Curr Med Chem; 2001 Jan 01; 8(1):39-50. PubMed ID: 11172691
    [Abstract] [Full Text] [Related]

  • 7. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J, Wang FP, Wei H, Liu G.
    Cancer Chemother Pharmacol; 2005 Feb 01; 55(2):179-88. PubMed ID: 15378274
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P.
    Cancer Res; 2001 Jan 15; 61(2):749-58. PubMed ID: 11212278
    [Abstract] [Full Text] [Related]

  • 9. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
    Chen G, Teicher BA, Frei E.
    Anticancer Res; 1996 Jan 15; 16(6B):3499-505. PubMed ID: 9042212
    [Abstract] [Full Text] [Related]

  • 10. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB, Beck WT, Trent JM.
    Cancer Res; 1988 Jan 15; 48(2):393-8. PubMed ID: 2891436
    [Abstract] [Full Text] [Related]

  • 11. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 15; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 12. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.
    Life Sci; 2008 Nov 21; 83(21-22):700-8. PubMed ID: 18845169
    [Abstract] [Full Text] [Related]

  • 13. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
    Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, Yang X, Pan Q.
    Cancer Chemother Pharmacol; 2004 Apr 21; 53(4):349-56. PubMed ID: 14666379
    [Abstract] [Full Text] [Related]

  • 14. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL, Cao J, Starling JJ, Dantzig AH.
    Int J Cancer; 2003 Jan 01; 103(1):121-5. PubMed ID: 12455064
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein.
    Lee BD, Li Z, French KJ, Zhuang Y, Xia Z, Smith CD.
    J Med Chem; 2004 Mar 11; 47(6):1413-22. PubMed ID: 14998330
    [Abstract] [Full Text] [Related]

  • 16. Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives.
    Hayashi M, Koike K, Rho MC, Kuwano M, Kishiye T, Komiyama K.
    Anticancer Drug Des; 2001 Mar 11; 16(4-5):255-60. PubMed ID: 12049484
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM.
    Cancer Res; 1987 Oct 15; 47(20):5455-60. PubMed ID: 2888532
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Oct 15; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 19. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA, Nervi AM, Anthony SP, Kaltreider RC, Warren AJ, Pesce CA, Davis SA, Lariviere JP, Hamilton JW.
    Oncol Res; 1999 Oct 15; 11(7):303-10. PubMed ID: 10757444
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
    Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T.
    Cancer Res; 1993 Oct 01; 53(19):4595-602. PubMed ID: 8402633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.